Baker Bros. Advisors LP recently announced the acquisition of new stake in Hookipa Pharma Inc (NASDAQ:HOOK). The institutional investor has increased its shareholding in the Healthcare company by 82.25% to 8.07 million shares with purchase of 3.64 million shares. This fresh investment now brings its stake to 9.89% valued currently at $4.59 million. In addition, Morgan Stanley Smith Barney LLC raised its holdings by 0.19 million to 0.63 million shares.
With over 8.96 million Hookipa Pharma Inc (HOOK) shares trading Friday and a closing price of $0.72 on the day, the dollar volume was approximately $6.45 million. The shares have shown a negative half year performance of -7.34% and its price on 12/22/23 lost nearly -16.52%. Currently, there are 83.95M common shares owned by the public and among those 74.37M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 7 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 7 of these insider trades were purchases, accounting for 47,000 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Hookipa Pharma Inc are Vanguard Total Stock Market ETF, Fidelity VIP – Growth Portfolio, and Fidelity Capital Appreciation Fun. Vanguard Total Stock Market ETF owns 1.4 million shares of the company’s stock, all valued at over $0.79 million. Fidelity Capital Appreciation Fun now owns shares totaling to 1.12% of the shares outstanding.
Shares of Hookipa Pharma Inc (NASDAQ: HOOK) opened at $0.83, down -$0.03 from a prior closing price of $0.86. However, the script later moved the day high at 0.8900, down -16.52%. The company’s stock has a 5-day price change of 10.26% and 23.90% over the past three months. HOOK shares are trading -11.11% year to date (YTD), with the 12-month market performance down to -7.70% lower. It has a 12-month low price of $0.41 and touched a high of $2.05 over the same period. HOOK has an average intraday trading volume of 2.10 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 20.12%, 37.28%, and -9.60% respectively.
Institutional ownership of Hookipa Pharma Inc (NASDAQ: HOOK) shares accounts for 49.50% of the company’s 83.95M shares outstanding. Mutual fund holders own 7.52%, while other institutional holders and individual stakeholders account for 9.32% and 43.43% respectively.
It has a market capitalization of $60.44M and a beta (3y monthly) value of 0.98. The earnings-per-share (ttm) stands at -$0.89. Price movements for the stock have been influenced by the stock’s volatility, which stands at 19.38% over the week and 10.64% over the month.
Analysts forecast that Hookipa Pharma Inc (HOOK) will achieve an EPS of -$0.19 for the current quarter, -$0.22 for the next quarter and -$0.72 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.21 while analysts give the company a high EPS estimate of -$0.17. Comparatively, EPS for the current quarter was -$0.17 a year ago. Earnings per share for the fiscal year are expected to increase by 14.90%, and 14.54% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 5 brokerage firm advisors rate Hookipa Pharma Inc (HOOK) as a “Strong Buy” at a consensus score of 1.00. Specifically, 5 Wall Street analysts polled rate the stock as a buy, while 0 of the 5 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the HOOK, a number of firms have released research notes about the stock. BofA Securities stated their Underperform rating for the stock in a research note on December 02, 2022, with the firm’s price target at $0.50.
